MS News that Caught My Eye Last Week: 3rd Round of Lemtrada, Ampyra’s Possibilities, Long-term MD1003, Possible PML Treatment
#ACTRIMS2018 – Third Course of Lemtrada Improves Relapse, Disability in MS Patients, CARE-MS II Trial Shows The normal treatment regimen with Lemtrada is a series of two treatment courses, with the second infusion course given 12 months after the first. A “selling point” for this disease-modifying therapy (DMT) is…